{
    "clinical_study": {
        "@rank": "30181", 
        "arm_group": {
            "arm_group_label": "Oshadi D and Oshadi R", 
            "arm_group_type": "Experimental", 
            "description": "Anti tumor agents"
        }, 
        "brief_summary": {
            "textblock": "This study is single-arm, none randomized, open label, two-dose-cohorts, single center\n      clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in\n      patients with BCC. Patients will receive Oshadi D and Oshadi R for 60 -90 days until the\n      planned surgical excision of the lesion."
        }, 
        "brief_title": "Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "BCC", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Basal Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 21 years old with tissue confirmed diagnosis of local BCC.\n\n          -  Patient is candidate for surgical excision of the BCC in few months.\n\n          -  BCC lesion \u226510mm in its longest diameter.\n\n          -  Sexually active fertile patients and their partners must agree to use medically\n             accepted methods of contraception during therapy and 3 months after the last dose of\n             the study drugs.\n\n          -  Female patients of childbearing potential must have a negative pregnancy test at\n             screening.\n\n          -  Patient must understand and be willing to give written informed consent prior to any\n             study procedures or evaluations and be willing to adhere to all study schedules and\n             requirements.\n\n        Exclusion Criteria:\n\n          -  Uncontrolled Intercurrent illness or any history of significant cardiac, renal,\n             neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic\n             hepatic disease or any other disease which in the judgment of the investigator would\n             interfere with the study or confound the results.\n\n          -  Other active cancer disease.\n\n          -  Serum creatinine > 1.5 mg/dL for males and >1.4 mg/dL for females.\n\n          -  Female patient who are breastfeeding or have a positive pregnancy test at screening\n             or at any time during the study.\n\n          -  Any acute cardiovascular event during the last 6 months prior to inclusion.\n\n          -  Symptomatic congestive heart failure with ejection fraction < 30%.\n\n          -  Patient has prothrombin time/International Normalization Ration (PT/INR) or partial\n             thromboplastin time (PTT) test results > 1.3 UNL.\n\n          -  Hemoglobin \u2264  11 g/dL\n\n          -  Platelets < 150,000 per microliter\n\n          -  White blood cell count<3,000 x109/L and/or absolute neutrophils count <1.5 x 109/L\n\n          -  Significant swallowing disorders.\n\n          -  History of small bowel surgery.\n\n          -  Any history of pelvic or abdominal radiation.\n\n          -  Pre-existing mal-absorption syndrome, irritable bowel syndrome or other clinical\n             situation which could affect oral absorption.\n\n          -  Mental disorders.\n\n          -  Inability to give written informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007317", 
            "org_study_id": "OS-BCC-P2-01"
        }, 
        "intervention": {
            "arm_group_label": "Oshadi D and Oshadi R", 
            "description": "Anti tumor agents", 
            "intervention_name": "Oshadi D & Oshadi R", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antineoplastic Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "BCC", 
        "lastchanged_date": "December 9, 2013", 
        "location": {
            "contact": {
                "email": "hanna@oshadi-da.com", 
                "last_name": "Hanna Levy, Dr.", 
                "phone": "+972-52-282-4966"
            }, 
            "facility": {
                "address": {
                    "city": "Zrifin", 
                    "country": "Israel"
                }, 
                "name": "Assaf-Harofeh Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R in Patients With Basal Cell Carcinoma (BCC) Prior to Tumor Excision- a Phase II Study", 
        "other_outcome": {
            "description": "To estimate the duration of treatment needed to achieve response", 
            "measure": "To estimate the duration of treatment to achieve response", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "overall_contact": {
            "email": "hanna@oshadi-da.com", 
            "last_name": "Hanna Levy, Dr", 
            "phone": "+972-52-2824966"
        }, 
        "overall_official": {
            "affiliation": "Assaf Harofeh Medical Center, Zrifin, Israel", 
            "last_name": "Lior Heller, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Adverse events and serious adverse events occurence", 
            "safety_issue": "Yes", 
            "time_frame": "treatment end (day 60 or 90)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007317"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The primary efficacy endpoint of this study is Overall Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "treatment end (day 60 or 90)"
        }, 
        "source": "Oshadi Drug Administration", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oshadi Drug Administration", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}